Evaluate COGT stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in COGT? | Glauxie AI

Q: What are the risks of investing in COGT?

Cogent Biosciences, Inc. (COGT) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Andrew R. Robbins. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase... Employees: 200,000.

Q: How much debt does COGT have?

Review COGT total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is COGT a good long-term investment?

Evaluate COGT as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in COGT?

🦉

Cogent Biosciences, Inc. (COGT)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOAndrew R. Robbins

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as...

Key Executives

Name	Title
Abb Hayden	Senior Vice President of Sales
Andrew R. Robbins	President, Chief Executive Officer & Director
Brad Barnett	Chief Technology Officer
Brad Fell	Senior Vice President of Chemistry
Christi Waarich	Senior Director of Investor Relations
Cole Pinnow	Chief Commercial Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

COGT Profile Financials

Is COGT stock safe? How much debt does COGT have? Is COGT a good long-term investment?